補償肝硬化（C型肝炎）市場規模、佔有率和成長分析：按診斷、治療、最終用戶、分銷管道和地區分類－產業預測（2026-2033 年）

2024 年全球補償肝硬化（C型肝炎）市值為 21.4 億美元，預計到 2025 年將成長至 23.5 億美元，到 2033 年將成長至 48.9 億美元，在預測期（2026-2033 年）內複合年成長率為 9.6%。

全球補償肝硬化（C）市場涵蓋了對慢性C型肝炎引起的無症狀性肝纖維化患者的診斷、治療和管理解決方案的需求，影響全球約7,100萬人。晚期肝功能衰竭帶來的經濟負擔正在加速對早期篩檢和監測的投資，尤其是在直接抗病毒藥物（DAA）顯著提高治療率的推動下。就地檢驗）的發展至關重要，因為它能夠實現及時診斷和治療，從而減少住院次數和相關費用。此外，人工智慧驅動的自動化正在透過增強數據分析、提高患者管理和改進決策來變革治療方法。諸如FibroScan自動化平台等尖端工具正在進一步最佳化管理流程，從而顯著推動補償肝硬化（C）領域的成長和效率提升。

全球補償肝硬化（C型肝炎）市場成長要素

民眾和醫療專業人員對補償肝硬化（C型肝炎）早期症狀的認知不斷提高，在促進快速診斷方面發揮著至關重要的作用，使更多患者能夠受益於新的治療方法。這種認知的增強促使醫療系統加大對預防性篩檢計畫的投入，為市場相關人員創造了有利環境，並維持了公立和私人醫療機構對尖端治療方案的穩定需求。因此，製藥公司加大了研發投入，而保險公司則尋求與及時干預的臨床獲益相符的報銷策略，最終推動了市場成長。

全球補償肝硬化（C型肝炎）市場限制

全球補償肝硬化（C型肝炎）市場面臨許多挑戰，包括大規模研究的高成本、複雜的生產流程以及治療方案的個人化。定價通常高於常用療法的基準價格，這給患者和醫療支付方都帶來了沉重的經濟負擔。這可能導致新療法的推廣延遲、醫保覆蓋範圍有限，以及患者傾向於依賴療效較差的替代療法。醫療機構往往優先考慮經濟因素，阻礙了創新療法的應用，最終限制了患者獲得最有效的補償肝硬化（C型肝炎）治療方案的機會。

全球補償肝硬化（C型肝炎）市場趨勢

全球補償肝硬化（C型肝炎）市場正經歷著向精準醫療的顯著轉變，這主要得益於人們對該疾病複雜遺傳和分子機制的深入了解。製藥公司日益專注於開發標靶治療從根本上抑制疾病進展。生物技術創新者與臨床研究網路之間的合作正在加速關鍵生物標記的發現，使醫療專業人員能夠有效地為每位患者量身定做治療方案。這種向精準醫療的演進不僅提高了治療效果並最大限度地減少了副作用，而且還提高了患者的用藥依從性，並透過策略合作將精準醫療確立為市場成長的關鍵驅動力。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 一手數據和二手數據的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 行業概覽
• 競爭環境概述

市場動態與展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

主要市場因素

• 關鍵成功因素
• 影響市場的因素
• 關鍵投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球補償肝硬化（C型肝炎）市場規模：依診斷分類。

• 臨床試驗
• 影像
• 切片檢查
• 非侵入性纖維化評估

全球補償肝硬化（C型肝炎）市場規模：依治療方法分類。

• 抗病毒治療
• 支持性護理
• 疾病監測

全球補償肝硬化（C型肝炎）市場規模：依最終用戶分類

• 醫院
• 肝病專科診所
• 門診部

全球補償肝硬化（C型肝炎）市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球補償肝硬化（C型肝炎）市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • GCC
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Gilead Sciences, Inc.
• F. Hoffmann-La Roche Ltd
• AbbVie Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• AstraZeneca PLC
• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Sanofi SA
• Bayer AG
• GlaxoSmithKline plc
• Madrigal Pharmaceuticals, Inc.
• Intercept Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals, Inc.
• Novo Nordisk A/S
• Ipsen SA
• Eisai Co., Ltd.

結論與建議

Global Compensated Cirrhosis Type C Market size was valued at USD 2.14 Billion in 2024 and is poised to grow from USD 2.35 Billion in 2025 to USD 4.89 Billion by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).

The global market for compensated cirrhosis type C encompasses the demand for diagnostics, therapeutics, and management solutions for patients with asymptomatic liver fibrosis caused by chronic hepatitis C, affecting approximately 71 million people worldwide. The economic burden from advanced liver failure has accelerated investments in early-stage screening and monitoring, particularly following advancements in direct-acting antivirals that significantly improve cure rates. The growth of point-of-care testing is crucial, as it facilitates timely diagnosis and treatment, consequently reducing hospital admissions and associated costs. Additionally, AI-driven automation is transforming treatment approaches by enhancing data analysis, streamlining patient management, and improving decision-making. Cutting-edge tools like automated FibroScan platforms are further optimizing the management pathways, fostering significant growth and efficiency within the compensated cirrhosis type C landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Compensated Cirrhosis Type C market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Compensated Cirrhosis Type C Market Segments Analysis

Global compensated cirrhosis type c market is segmented by diagnosis, treatment, end user, distribution channel and region. Based on diagnosis, the market is segmented into Laboratory Testing, Imaging, Liver Biopsy and Non-Invasive Fibrosis Assessment. Based on treatment, the market is segmented into Antiviral Therapy, Supportive Care and Disease Monitoring. Based on end user, the market is segmented into Hospitals, Specialty Liver Clinics and Ambulatory Care Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Compensated Cirrhosis Type C Market

The growing awareness among both the public and healthcare professionals about the early symptoms of compensated cirrhosis type C plays a crucial role in facilitating prompt diagnoses, thus increasing the number of patients who can benefit from new therapies. This increased attention encourages healthcare systems to invest in preventive screening initiatives, creating a conducive environment for market players and maintaining a steady demand for cutting-edge treatment solutions in both private and public domains. As a result, pharmaceutical companies are more inclined to channel investments into research and development, while insurers are likely to explore reimbursement strategies that resonate with the clinical advantages of timely interventions, ultimately supporting market growth.

Restraints in the Global Compensated Cirrhosis Type C Market

The Global Compensated Cirrhosis Type C market faces significant challenges due to the high costs associated with extensive research, intricate manufacturing processes, and the tailored nature of therapies. These pricing structures often surpass typical treatment benchmarks, resulting in affordability issues for both patients and healthcare payers. As a result, there can be delays in adopting new treatments, limitations in formulary inclusion, and a tendency to rely on less effective alternatives. Healthcare institutions frequently prioritize financial considerations, which may impede the integration of innovative therapies, ultimately restricting patient access to the most effective options for managing compensated cirrhosis type C.

Market Trends of the Global Compensated Cirrhosis Type C Market

The Global Compensated Cirrhosis Type C market is witnessing a substantial trend towards personalized therapeutics, propelled by a deeper understanding of the intricate genetic and molecular mechanisms underlying the disease. Pharmaceutical companies are increasingly focused on developing targeted therapies that tackle disease progression directly at its core. Collaborative efforts between biotech innovators and clinical research networks are facilitating the discovery of critical biomarkers, enabling healthcare providers to customize treatment plans for individual patients effectively. This evolution toward precision medicine not only enhances treatment efficacy and minimizes adverse effects but also promotes sustained patient adherence, establishing personalized therapeutics as a vital driver of market growth through strategic collaborations.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Compensated Cirrhosis Type C Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Laboratory Testing
• Imaging
• Liver Biopsy
• Non-Invasive Fibrosis Assessment

Global Compensated Cirrhosis Type C Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Antiviral Therapy
• Supportive Care
• Disease Monitoring

Global Compensated Cirrhosis Type C Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Liver Clinics
• Ambulatory Care Centers

Global Compensated Cirrhosis Type C Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Compensated Cirrhosis Type C Market Size & CAGR (2026-2033)

• North America (Diagnosis, Treatment, End User, Distribution Channel)
  • US
  • Canada
• Europe (Diagnosis, Treatment, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Madrigal Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intercept Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations